{"id":463175,"date":"2026-02-12T00:34:21","date_gmt":"2026-02-12T00:34:21","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/463175\/"},"modified":"2026-02-12T00:34:21","modified_gmt":"2026-02-12T00:34:21","slug":"roche-details-non-inferiority-of-btk-inhibitor-in-multiple-sclerosis-trial-endpoints-news","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/463175\/","title":{"rendered":"Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial &#8211; Endpoints News"},"content":{"rendered":"<p><a href=\"https:\/\/news.google.com\/rss\/articles\/CBMivAFBVV95cUxQZ3pSQnJTX0d1MWc2WENDTWltd1BybFRBSE5VSjNEZXczVjlKb3d1bmswenJPMnZWOG13S053emRDY3ppRkppSmpFVkxrQUFGbm9SNF9RMTNla1licWdnMjVuRVFoTURGMjYtRENlSnN5bkhPSTIzVVAwVlFGczdITmhJVFVYcjlkaWxzTXBIdmxnUEt5YjNkRFZFaTJWaWhiLUV1S19seElVR3h0TUFiMjZNZkU0bGRIckVjcg?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial<\/a>&nbsp;&nbsp;Endpoints News<a href=\"https:\/\/news.google.com\/rss\/articles\/CBMirgFBVV95cUxPbnFJZzRQbGxabFBYTFpjc3VKNFJqcjBENGRMeG51N0x6MTROVmNtNjJWUmxWd21LX01KTVUtN1BSY2liSW5BODd0MzFCNENFU2JzUkRnblp4blRXd2lPbXhoTGQxTUEweUZRNEY3UkdnZ1VQRGktZUJhSmpYWGpZNFRsbHBvNk9wWnUtSEg0aUFYLWIxTm15OXVQOWo5d2ZDSDdMYW9fTVNQZ1FnTmc?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Roche unveils data behind BTK inhibitor&#8217;s phase 3 multiple sclerosis win in Ocrevus trial<\/a>&nbsp;&nbsp;Fierce Biotech<a href=\"https:\/\/news.google.com\/rss\/articles\/CBMisAFBVV95cUxPalZBUnoxNWQ3bnI0bUtfTmt3Y2x2U0FqSVYyRFlhVnZLeEhGY3BKRUhWeTRKM19mTHY3alliaUsta2gyOWtUOGd4aklEeDhMYWVMYjc2dXB4OHpXcDRLQmNEMnhvWVRpdkFLU0lzNUpGall4dEdBOGNwbnd5NWFzR2hsRThNQXhBS1Q3MTMtTDNWS0F1djBPTk1JMFJvcG91V2M3bHMxVUVEMkZfeUtZVQ?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">ACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial<\/a>&nbsp;&nbsp;Multiple Sclerosis News Today<a href=\"https:\/\/news.google.com\/rss\/articles\/CBMipgFBVV95cUxPai1xR0dpalIxenctZzNRUUk4X1Z0R2hNN1dtWnFMZGtBbGJva1l3R2h1dEhobm5fbEU0eU4yWlV4ZlpVV2dsa2RUenVDWnJvaTRzdnRuQU5GdDBLTWhkb0JkM1dva2twVFpJSk5QdnpUWTVzMlNIMXluSnYtbGtIbkp4UjNzOFQ0bWZpWFRvaHh2MkNJWmVFaFhfdF9rd0ZzbGRxUkJn?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Genentech plans NDA for multiple sclerosis pill with study win<\/a>&nbsp;&nbsp;BioWorld MedTech<a href=\"https:\/\/news.google.com\/rss\/articles\/CBMimwJBVV95cUxQZE9XMDNMTG1BcllfV2VXeFQ3OUlCMXdmTFBIZGx1SnJPcTBOTktxQnRJQWJtMHF3VlRYV2ZPSjNocWpwb1N2bzBqdWFyRUVGZjdGNzhFbTlTUEZlRFF4N3JCTkdkQTNHbmg2UVdfVGNLX2daT0JWSjlLczQ1QmxJcGxhNWQtZVhMRkxsVzZYMDh2SDNxLW54SGoxaDF4V2JfS1FNa05Yc01ZM05yVXdDazBpS1pvNVE3Y3FYNEFDb1pYVjN6Tmh5SUNlWGJsc3I5bVNZQkJaQkZmVEpsa2ZPQWlDRTRwVmprb3YzT1NJbEN5Qm1tZjFCVGVxeXczTDRMN3JtM2lMN2RiVGVlYXJ4WHNINjJ3TzhRcmdv?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">RO: Fenebrutinib matched ocrelizumab in PPMS efficacy and offers a promising oral high-efficacy MS option<\/a>&nbsp;&nbsp;TradingView<\/p>\n","protected":false},"excerpt":{"rendered":"Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial&nbsp;&nbsp;Endpoints NewsRoche unveils data behind BTK inhibitor&#8217;s phase 3&hellip;\n","protected":false},"author":2,"featured_media":463176,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[58],"tags":[215817,215818,215820,97,243,5004,215816,956,215815,40589,24637,161600,215819],"class_list":["post-463175","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-btk-inhibitor","tag-fenebrutinib","tag-fentrepid","tag-health","tag-medication","tag-multiple-sclerosis","tag-ocrevus","tag-pharma","tag-ppms","tag-rd","tag-roche","tag-sanofi","tag-tolebrutinib"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/463175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=463175"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/463175\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/463176"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=463175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=463175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=463175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}